Ligand to Hold Third Quarter Results Conference Call on November 5

• Press Release
• Source: Ligand Pharmaceuticals Incorporated
• On 4:15 pm EDT, Monday October 26, 2009

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced today that it plans to report third quarter 2009 financial results on Thursday, November 5, 2009, following the close of market. Ligand’s President and CEO, John L. Higgins, Vice President of Finance and CFO, John Sharp and Vice President of Discovery Research, Dr. Martin Meglasson will host the conference call.

Related Quotes

Symbol	Price	Change
LGND	2.02	-0.11

{"s" : "lgnd","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world’s largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, Pfizer and Wyeth Pharmaceuticals. With more than 20 molecules in various stages of development, Ligand utilizes proprietary technologies for identifying drugs with novel receptor and enzyme drug targets.

Ligand Pharmaceuticals Incorporated
John L. Higgins, President and CEO or
Erika Luib, Investor Relations
(858) 550-7896
or
Lippert/Heilshorn & Associates
Don Markley
dmarkley@lhai.com
(310) 691-7100